No ratings yet
Taught by or worked with Antonio? Your rating helps other students choose.
Professor Antonio Vidal-Puig is Professor of Molecular Nutrition and Metabolism at the University of Cambridge, where he leads the TVP Lab within the Institute of Metabolic Science. He also serves as an Honorary Consultant in Metabolic Medicine at Addenbrooke’s Hospital and holds the position of Director of the Cardiometabolic Programme at the Heart and Lung Research Institute. His research programme investigates the molecular mechanisms linking obesity to cardiometabolic complications, with particular emphasis on adipose tissue dysfunction, lipotoxicity, brown adipose tissue activation, and nutrient partitioning.
Professor Vidal-Puig earned his medical degree from the University of Valencia Medical School and completed endocrinology training at the University of Granada Medical School. He undertook postdoctoral research at Massachusetts General Hospital and Beth Israel Hospital, Harvard Medical School, from 1992 to 1999. In 2015 he completed an Executive MBA at the Cambridge Judge Business School. He established his independent laboratory at Cambridge in 2000 and has held additional appointments including Associate Faculty at the Wellcome Sanger Institute and honorary professorships at institutions in China, Japan, and Singapore. Among his honours are election as a Fellow of the Academy of Medical Sciences in 2014, the FEBS National Lecture in 2015, the Society for Endocrinology Medal in 2017, the Lilly Foundation Distinguished Career Award, and the degree of Doctor honoris causa from King Juan Carlos University in 2024. He has authored or co-authored numerous publications in leading journals, including recent work in Nature Metabolism on murine models of metabolic dysfunction-associated steatotic liver disease, and co-edited the volume A Systems Biology Approach to Study Metabolic Syndrome in 2014.
Explore the Cambridge University study in eClinicalMedicine showing patients regain 60% of lost weight within a year after stopping GLP-1 drugs like Ozempic and Wegovy. Insights on mechanisms, UK NHS rollout, and maintenance strategies.
Photo by Precondo CA on Unsplash
Photo by Brecht Corbeel on Unsplash
Photo by Anne Nygård on Unsplash
Photo by Kelly Sikkema on Unsplash
Photo by Markus Winkler on Unsplash
Photo by Philip Strong on Unsplash
